Immunocore Holdings plc (NASDAQ:IMCR) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Immunocore Holdings plc (NASDAQ:IMCR) have been assigned a consensus recommendation of “Moderate Buy” from the thirteen research firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and eight have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $65.64.

Several equities analysts have issued reports on IMCR shares. Needham & Company LLC reiterated a “buy” rating and set a $71.00 target price on shares of Immunocore in a research report on Friday, January 10th. Mizuho cut Immunocore from an “outperform” rating to a “neutral” rating and cut their price objective for the stock from $72.00 to $38.00 in a research report on Monday, November 11th. HC Wainwright restated a “buy” rating and set a $100.00 target price on shares of Immunocore in a research report on Monday, January 27th. Morgan Stanley reiterated an “equal weight” rating and issued a $35.00 price target (down previously from $74.00) on shares of Immunocore in a report on Friday, December 13th. Finally, Guggenheim downgraded shares of Immunocore from a “buy” rating to a “neutral” rating in a report on Monday, October 7th.

Institutional Investors Weigh In On Immunocore

Hedge funds have recently modified their holdings of the company. Exchange Traded Concepts LLC grew its holdings in Immunocore by 40.4% in the 3rd quarter. Exchange Traded Concepts LLC now owns 5,075 shares of the company’s stock valued at $158,000 after buying an additional 1,461 shares during the period. Connective Portfolio Management LLC purchased a new stake in Immunocore in the third quarter valued at approximately $218,000. China Universal Asset Management Co. Ltd. increased its position in Immunocore by 69.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 7,433 shares of the company’s stock worth $231,000 after purchasing an additional 3,053 shares during the last quarter. GSA Capital Partners LLP purchased a new position in Immunocore during the third quarter worth approximately $406,000. Finally, Alpha DNA Investment Management LLC acquired a new position in shares of Immunocore in the 3rd quarter valued at $411,000. 84.50% of the stock is owned by institutional investors and hedge funds.

Immunocore Stock Down 5.2 %

IMCR opened at $31.17 on Thursday. The business has a 50 day moving average price of $30.52 and a two-hundred day moving average price of $33.01. Immunocore has a 52 week low of $27.69 and a 52 week high of $76.14. The company has a market cap of $1.56 billion, a PE ratio of -32.81 and a beta of 0.77. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03.

Immunocore (NASDAQ:IMCR) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.17 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.50. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The firm had revenue of $80.25 million for the quarter, compared to analyst estimates of $78.94 million. During the same period last year, the firm posted ($0.59) EPS. Immunocore’s quarterly revenue was up 23.7% on a year-over-year basis. As a group, research analysts anticipate that Immunocore will post -0.94 EPS for the current year.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.